Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 9/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14119869 | 0.84 | LMNA (0.73) | LMNASMN1; SMN2KMT2AMAPTRAB9A | |
| SCHEMBL501925 | 0.84 | LMNA (1.00) | LMNASMN1; SMN2KMT2AMAPTMEN1 | |
| SCHEMBL14119932 | 0.83 | LMNA (1.00) | LMNASMN1; SMN2KMT2AMAPTRAB9A | |
| SCHEMBL501922 | 0.82 | NPC1 (0.73) | LMNASMN1; SMN2KMT2AMAPTRAB9A | |
| SCHEMBL14119898 | 0.82 | LMNA (1.00) | LMNASMN1; SMN2MAPTALDH1A1GAA | |
| SCHEMBL14119621 | 0.81 | LMNA (1.00) | LMNASMN1; SMN2KMT2AMAPTRAB9A | |
| SCHEMBL14119465 | 0.80 | MAPT (0.70) | LMNASMN1; SMN2KMT2AMAPTMEN1 | |
| SCHEMBL14119589 | 0.80 | LMNA (0.73) | LMNASMN1; SMN2KMT2AMAPTMEN1 | |
| SCHEMBL1943283 | 0.79 | CCR2 (0.77) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL14120354 | 0.78 | ALDH1A1 (0.70) | LMNASMN1; SMN2KMT2AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106058-B2 | Anti-arenaviral compounds | SIGA TECHNOLOGIES, INC. (US) | 2012-01-31 | — | — | US | claimed |
| US-20140301979-A1 | ANTI-ARENAVIRAL COMPOUNDS | SIGA TECHNOLOGIES, INC., (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140301979-A1 | ANTI-ARENAVIRAL COMPOUNDS | SIGA TECHNOLOGIES, INC., (US) | 2014-10-09 | — | — | US | disclosed |
| US-8791110-B2 | Anti-arenaviral compounds | SIGA TECHNOLOGIES, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8791110-B2 | Anti-arenaviral compounds | SIGA TECHNOLOGIES, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8518951-B2 | Anti-arenaviral compounds | SIGA TECHNOLOGIES, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518951-B2 | Anti-arenaviral compounds | SIGA TECHNOLOGIES, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120308519-A1 | Anti-Arenaviral Compounds | SIGA TECHNOLOGIES, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120308519-A1 | Anti-Arenaviral Compounds | SIGA TECHNOLOGIES, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120107276-A1 | Anti-Arenaviral Compounds | SIGA TECHNOLOGIES, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120107276-A1 | Anti-Arenaviral Compounds | SIGA TECHNOLOGIES, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8106058-B2 | Anti-arenaviral compounds | SIGA TECHNOLOGIES, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106058-B2 | Anti-arenaviral compounds | SIGA TECHNOLOGIES, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106058-B2 | Anti-arenaviral compounds | SIGA TECHNOLOGIES, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20090180980-A1 | Anti-Arenaviral Compunds | SIGA TECHNOLOGIES, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090180980-A1 | Anti-Arenaviral Compunds | SIGA TECHNOLOGIES, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| WO-2007120374-A2 | ANTI-ARENAVIRAL COMPOUNDS | SIGA TECHNOLOGIES, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107276-A1 | Anti-Arenaviral Compounds | ZC3HAV1, CNBP, EIF2AK2 | LMNA 2616/4885SMN1; SMN2 1463/4885KMT2A 590/4885 |
| US-20090180980-A1 | Anti-Arenaviral Compunds | ZC3HAV1, EIF2AK2, CNBP | LMNA 2806/4885SMN1; SMN2 1200/4885KMT2A 546/4885 |
| US-20120308519-A1 | Anti-Arenaviral Compounds | ZC3HAV1, CNBP, EIF2AK2 | LMNA 2616/4885SMN1; SMN2 1463/4885KMT2A 590/4885 |
| US-20140301979-A1 | ANTI-ARENAVIRAL COMPOUNDS | ZC3HAV1, CNBP, EIF2AK2 | LMNA 2616/4885SMN1; SMN2 1463/4885KMT2A 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.